T follicular helper (Tfh) cells are a subset of T cells carrying the CD4 antigen; they are important in supporting plasma cell and germinal centre responses 1,2 . The initial induction of Tfh cell properties occurs within the first few days after activation by antigen recognition on dendritic cells, although how dendritic cells promote this cell-fate decision is not fully understood 1,2 . Moreover, although Tfh cells are uniquely defined by expression of the follicle-homing receptor CXCR5 (refs 1, 2), the guidance receptor promoting the earlier localization of activated T cells at the interface of the B-cell follicle and T zone has been unclear 3-5 . Here we show that the G-protein-coupled receptor EBI2 (GPR183) and its ligand 7α,25-dihydroxycholesterol mediate positioning of activated CD4 T cells at the interface of the follicle and T zone. In this location they interact with activated dendritic cells and are exposed to Tfhcell-promoting inducible co-stimulator (ICOS) ligand. Interleukin-2 (IL-2) is a cytokine that has multiple influences on T-cell fate, including negative regulation of Tfh cell differentiation 6-10 . We demonstrate that activated dendritic cells in the outer T zone further augment Tfh cell differentiation by producing membrane and soluble forms of CD25, the IL-2 receptor α-chain, and quenching T-cell-derived IL-2.
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Upregulation of the co-stimulatory molecules ICOS and OX40 also occurred to an equivalent extent (Extended Data Fig. 2a ). Proliferation began by day 2 and at this time point the WT and EBI2 KO cells responded similarly (Fig. 2b, c) . However, by day 3, the EBI2-deficient cells were undergoing less proliferation and their numbers increased more slowly (Fig. 2b, c) . This was not due to a direct effect of 7α,25-OHC on T-cell proliferation (Extended Data Fig. 2b, c) . Tracking of differentiation markers on the in vivo activated T cells revealed that EBI2 KO cells were compromised in their induction of a Tfh cell phenotype, as assessed by CXCR5, PD-1 (Fig. 2d, e ), Bcl6, and Il21 expression (Extended Data Fig. 2d-f ). EBI2-deficient OTII T cells also differentiated less efficiently into Tfh cells in lymph nodes (Fig. 2f ). We also observed reduced Tfh cell responses to Listeria-OVA, reduced polyclonal EBI2 KO Tfh cell responses to SRBCs and reduced germinal centre and plasma cell responses to these antigens (Supplementary Information and Extended Data Fig. 3a-j) . Tfh cell differentiation is promoted by interaction both with dendritic cells (DCs) and with B cells, and time-course studies indicate that DCs are critical early while B cells play a later role 1, 2 . Consistent with these requirements, WT OTII T cells showed a partial reduction in Tfh cell differentiation at day 3 of the response in MD4 immunoglobulin (Ig)-transgenic mice lacking cognate B cells capable of OVA antigen presentation to OTII T cells (Fig. 3a) . Importantly, however, EBI2 KO OTII T cells formed fewer Tfh cells than WT OTII T cells in the MD4 recipients, indicating that T-cell EBI2 expression augmented Tfh cell development at early time points in a B-cell-independent manner.
Similar observations were made in B-cell-deficient μMT mice (Extended Data Fig. 4a ). These findings led us to test whether EBI2 was required in T cells for some type of interaction with DCs. Ablation of DCs using Zbtb46-diphtheria toxin receptor (DTR) mice 15 caused a complete block in Tfh cell generation (Extended Data Fig. 4b, c) , consistent with previous studies using other DC ablation approaches 16 . Splenic CD4 and DCIR2 co-expressing DCs re-localize from bridging channels to the outer T zone within 6 h of immunization with SRBCs 17, 18 , and the cells remain in this region for at least 2 days ( Fig. 3b and Extended Data Fig.  4d ). At 12 h, day 1 and day 2 time points, almost the entire population of activated WT OTII T cells co-localized with the activated DCIR2 + DCs (Fig. 3b, c and Extended Data Fig. 4e ). By contrast, activated EBI2 KO T cells were broadly distributed and only partly overlapped with the DCIR2 + DCs (Fig. 3b, c Fig. 4e , at the indicated times after immunization. d, Icosl mRNA abundance in splenic CD4 + and CD8 + CD11c + DCs from mice immunized 12 h earlier with saline or SRBCs, shown relative to the saline control. e, Summary data of ICOSL surface levels for DCs of the type in d from mice also treated with control or ICOS blocking antibody. f, ICOSL surface levels on CD4 + splenic DCs from mice that had received WT or EBI2 KO OTII T cells, 12 h after immunization with SRBC-OVA. Recipient mice were CD28 KO. See Supplementary Information for details. g, Frequency and number CXCR5 + PD-1 hi WT and EBI2 KO OTII T cells in spleens from mice treated with ICOS blocking antibody, analysed at day 3 after immunization. *P < 0.05 and **P < 0.01 by ANOVA (a-d, e) or Student's t-test (f, g). Data are representative of three (a-c) or two (d-g) experiments with at least three (a, c-g) or two (b) mice per group (error bars (d), s.e.m.).
with deficiencies in DCs, we established that CD4 + but not CD8 + DCs were important for Tfh cell induction by SRBC-OVA (Supplementary Information and Extended Data Fig. 4f -k).
ICOS signalling is important for Tfh cell differentiation 1,2 and splenic DCs upregulated ICOS ligand (ICOSL) mRNA after activation by SRBCs, with the extent of upregulation being greater in CD4 + than CD8 + DCs (Fig. 3d ). However, flow cytometric analysis showed CD4 + DCs activated for 12 h had low surface ICOSL staining ( Fig. 3e and Extended Data Fig. 4l ). Since ICOSL undergoes rapid ecto domain shedding after ICOS engagement 19, 20 , we considered the possibility that surface levels were reduced because of interactions with ICOS-high activated T cells. Consistent with this idea, when SRBC-immunized mice were also treated with an ICOS blocking antibody to prevent ICOS-induced ICOSL shedding 19, 20 , CD4 + but not CD8 + DCs showed increased ICOSL surface abundance compared with unimmunized mice ( Fig. 3e and Extended Data Fig. 4l ). We took advantage of the sensitivity of ICOSL to ICOS-induced shedding as a method to measure the amount of interaction between DCs and cognate T cells. Twelve hours after SRBC-OVA immunization, ICOSL levels were higher on CD4 + DCs in mice harbouring EBI2-deficient OTII T cells than WT OTII T cells ( Fig. 3f ). These data suggest that the reduced Tfh differentiation of EBI2 KO OTII T cells occurs at least in part because of lower ICOS engagement with ICOSL on CD4 + DCs. However, in mice treated with an ICOS blocking antibody, although Tfh differentiation of control OTII T cells was reduced, EBI2-deficient OTII T cells were still more defective (Fig. 3g ), indicating an ICOSindependent influence of EBI2 in augmenting Tfh cell fate. An assessment of mRNA levels of other factors established to have an effect on Tfh differentiation (IL-6, transforming growth factor-β (TGF-β)) showed that they were similarly expressed in CD4 + and CD8 + DCs and they were therefore not considered likely factors accounting for the EBI2-dependence of Tfh cell differentiation (Extended Data Fig. 4n ). 
To search for surface or secreted DC-derived factors that might augment Tfh cell differentiation, we performed RNA sequencing (RNA-seq) analysis on CD4 + DCs from the spleens of saline or SRBC immunized mice. This analysis revealed CD25, the high affinity IL-2 receptor α-chain, as one of the most strongly induced genes in SRBC-activated DCs (Extended Data Fig. 5a ). CD25 mRNA induction occurred rapidly after immunization and remained elevated for at least 2 days (Fig. 4a ), and many CD4 + DCs were surface positive for CD25 over this time frame (Fig. 4b ). CD8 + DCs showed little induction of CD25 mRNA or protein under these immunization conditions (Fig. 4a, b ). Analysis of lymph node DCs after OVA plus alum immunization revealed upregulation of CD25 on migratory CD11b + DCs at day 1 and 2 (Extended Data Fig. 5b ). Staining of spleen sections identified CD25 + cells in the unstimulated T zone that are likely CD25 hi regulatory T cells, but also showed broad induction of CD25 in the outer T zone within 12 h of SRBC immunization in a pattern resembling the DCIR2 + DC distribution (Fig. 4c ). Similar appearance of CD25 staining in the T zone was seen in T-cell-deficient mice, providing evidence that expression by activated DCs was being detected (Extended Data Fig. 5c ). CD25 needs to associate with CD122 (IL-2Rβ) and IL-2Rγ to transmit signals in response to IL-2 (ref. 10) . Despite expression of CD25, activated CD4 + DCs showed minimal CD122 mRNA and protein expression and they did not respond to IL-2 as assessed by intracellular pSTAT5 staining (Extended Data Fig. 5d-f ). These data led us to consider the possibility that activated DCs express CD25 to alter IL-2 availability in the outer T zone.
IL-2 has pleiotropic roles in directing T-cell fate, including a negative influence on Tfh cell differentiation [6] [7] [8] [9] [10] . Despite equivalent IL-2 production and receptor expression (Supplementary Information and Extended Data Fig. 5g-i) , EBI2 KO T cells showed more IL-2R signalling than WT T cells at day 1 after immunization, as evidenced by higher pSTAT5 levels ( Fig. 4d ), suggesting that the EBI2 KO T cells were being exposed to more IL-2. The elevated induction of pSTAT5 in EBI2 KO T cells was also seen in lymph nodes after immunization with alum-OVA ( Fig. 4e ). Blimp1, encoded by Prdm1, is induced by IL-2 and negatively regulates expression of Bcl6, a factor essential for Tfh cell development 2 . In agreement with higher IL-2 exposure, the EBI2 KO T cells showed greater Prdm1 expression at day 3 (Extended Data Fig. 5j ).
The above findings led us to test whether DCs antagonize IL-2 availability to activated T cells in the outer T zone. Consistent with this possibility, when in vivo activated DCs were incubated briefly in vitro they were found to release soluble CD25 (sCD25) into the culture supernatant ( Fig. 4f ). DC production of sCD25 was not dependent on interaction with T cells (Fig. 4f ). Analysis of spleen tissue extracts showed elevated sCD25 production at 6 h after SRBC immunization and this was maintained at 24 h ( Fig. 4g ) and occurred in a T-cell-independent and DC-dependent manner (Fig. 4h ). To determine whether the sCD25 functioned as an IL-2 antagonist, supernatants from cultures of activated CD4 + DCs were tested in a bioassay for their ability to inhibit IL-2R signalling. Regulatory T cells were used as the reporter cells in this bioassay since they were more sensitive to low-dose IL-2 than Tfh cells (J.L. and J.G.C., unpublished observations). Supernatants from cultured SRBC-activated WT but not CD25 KO CD4 + DCs were able to antagonize IL-2R signalling in T cells (Extended Data Fig. 5l ).
To determine whether DCs were regulating T-cell differentiation in vivo by production of CD25, we generated bone marrow (BM) chimaeric mice that lacked CD25 in DCs (Supplementary Information and Extended Data Fig. 6a-e ). In these recipients, control (EBI2 Het) OTII T cells were compromised in their ability to take on a Tfh cell fate whereas EBI2 KO T cells were only mildly affected (Fig. 4i ). Staining of tissue sections from the DT-treated BM chimaeras established that the high CD25 abundance in the outer T zone was dependent on CD25 expression by DCs (Extended Data Fig. 6f ). Splenic Tfh cell responses to Listeria-OVA and lymph node Tfh cell responses to alum-OVA were also diminished in mice lacking CD25 on DCs (Extended Data Fig. 6g, h) . Moreover, mice lacking CD25 in DCs and harbouring transgenic B cells specific for hen egg lysozyme (HEL) mounted reduced plasma cell and germinal centre responses to HEL-conjugated SRBCs (Fig. 4j and Extended Data Fig. 6i, j) , which was associated with reduced serum anti-HEL IgG1 and IgG2b antibody levels (Fig. 4k ). To further test whether reduced exposure of EBI2 KO T cells to sCD25 could account for the defective Tfh cell induction, we treated mice with recombinant sCD25 at day 0 and 1 of the OTII T-cell response to SRBC-OVA. This treatment was sufficient to elevate sCD25 levels in tissue extracts (Extended Data Fig. 6k ), to antagonize pSTAT5 over-induction in the EBI2 KO T cells ( Fig. 4l ) and to partly rescue Tfh cell differentiation (Fig. 4m) . A full restoration of the Tfh response was not expected given that EBI2-deficient cells are also compromised in accessing ICOSL and possibly other Tfh-cell-promoting signals from cells in the outer T zone.
This work establishes a role for EBI2 and 7α,25-OHC in positioning activated T cells at the follicle-T-zone interface, promoting contact with Tfh cell-priming ICOSL hi CD25 + DCs (Supplementary Information and Extended Data Fig. 7) . Given that interactions both with DCs and with B cells are important for full Tfh cell differentiation 1,2 , we suggest that T-cell EBI2 upregulation initially acts to favour interaction with Tfh-cell-promoting DCs and subsequently with activated B cells. While EBI2 upregulation is important for Tfh cell induction, the receptor is downregulated at week 2 of the response and this may facilitate Tfh cell retention in germinal centres 14 . Soluble CD25 was first detected in human serum ~30 years ago and it has since been reported in human and mouse serum in many studies and correlated with various disease conditions [21] [22] [23] . Although there has been evidence that sCD25 can antagonize certain IL-2 functions 10, 22, 24 , the significance of sCD25 in vivo has been unclear. Moreover, the function of CD25 in myeloid cells has been mysterious 10, 25, 26 , with some in vitro studies suggesting it suppresses 27 and others that it augments 28, 29 T-cell responses. We show that DC production of CD25 plays an important role in quenching IL-2 in the outer T zone and it thereby cooperates with other factors, including ICOSL, to facilitate Tfh cell differentiation (Extended Data Fig. 7 ). While our findings show DCs produce sCD25, we do not exclude the possibility that membrane-associated CD25 on DCs also has a regulatory role. Strengths of IL-2 signalling influence Treg cell activity, Th17, Th1 and Th2 cell development, and CD8 T-cell proliferation and differentiation 10, 30 . We suggest that CD25-mediated IL-2-quenching by DCs will be a general mechanism acting to guide a range of IL-2-sensitive cell activation and differentiation processes.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

METHODS
Mice and bone marrow chimaeras.
Wild-type C57BL/6NCr and C57BL/6-cBrd/ cBrd/Cr (B6-Ly5.2) mice of 7-9 weeks of age were purchased from the National Cancer Institute. Ebi2 −/− (containing a green fluorescent protein (GFP) reporter in place of the Ebi2 coding exon), Cyp7b1 −/− , Ch25h −/− , Hsd3b7 −/− , Ccr7 −/− , HEL-specific MD4 Ig-transgenic, HEL-specific Hy10 mice and OVA-specific OTII TCR-transgenic mice have been described (refs 11, 17 , 31 and references therein). B-cell-deficient μMT mice were provided by T. Defranco and C. Allen. Cd28 −/− mice were provided by K. M. Ansel. TCRβδ −/− , Cd47 −/− , Batf3 −/− and Zbtb46-DTR mice were from Jackson Laboratories. Irf4 fl/fl CD11c-Cre + mice were from Jax and provided by S. Sanjabi. Cd25 −/− mice were from Jax and provided by M. Muschen. BM chimaeras were generated as described 11 and analysed after 6-12 weeks. Mixed BM chimaeras were made by mixing equal amounts of the two types of BM before transfer. The sample sizes were guided by previous studies in our laboratory. No animals were excluded from analysis, and sample size estimates were not used. The mouse genotype was not blinded from the investigator. Mice of a given genotype were randomly assigned to groups. However, littermate mice were evenly distributed into control or treatment groups and mice of both groups were co-caged whenever possible. In experiments involving transfers of OTII T cells, since the TCR transgene is on the Y chromosome, male mice were used as donors and recipients. In other experiments, similar numbers of male and female mice were used. All mice were adult and were studied between 7 and 20 weeks of age. Animals were housed in a specific-pathogen free environment in the Laboratory Animal Research Center at the University of California, San Francisco, and all experiments conformed to ethical principles and guidelines approved by the Institutional Animal Care and Use Committee. Adoptive transfer, immunizations, DC ablation and treatments. For analysis of CD4 + T-cell position, activation or Tfh cell differentiation in spleens, 1 × 10 6 to 5 × 10 6 WT and/or EBI2 KO OTII cells were adoptively transferred into mice. One day after cell transfer, recipients were immunized intraperitoneally with 2 × 10 8 SRBCs (Colorado Serum Company) conjugated with OVA (Sigma-Aldrich) as described 32 with minor modifications detailed below, with 25 μg OVA plus 25 μg lipopolysaccharide (Escherichia coli 0111:B4, Sigma-Aldrich), intravenously with 2 × 10 9 heat-killed Listeria-OVA as described 33 , or subcutaneously with 25 μg OVA in 200 μl Alum (InvivoGen). For conjugation of OVA with SRBCs, 1 ml of SRBCs was washed with PBS three times, incubated with 4 ml of 30 mg ml −1 ice-cold OVA in PBS and crosslinked with 1 ml of 100 mg ml −1 EDCI (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, Sigma-Aldrich) for 1 h on ice with occasional mixing, followed by washing four times in PBS to remove the free OVA and confirmation of the conjugation by flow cytometry. For HEL-specific antibody responses, 1 × 10 5 Hy10 B cells 34 were adoptively transferred into desired recipients. One day after cell transfer, recipients were intraperitoneally immunized with SRBCs conjugated with a low affinity mutant of HEL termed HEL2× (ref. 35 ) as described 17 . To visualize cell proliferation, cells were labelled with CellTrace violet tracer (Molecular Probes, Invitrogen) according to the manufacturer's instructions. For DC ablation, Zbtb46-DTR full or mixed chimaeras were injected intraperitoneally with 20 ng DT (Sigma-Aldrich) per gram of body weight 3 days before cell transfer and received 4 ng DT per gram of body weight on the third day after the initial DT injection and in some cases again 3 days later. To block ICOS, mice were injected intravenously with anti-mouse ICOS antibody (rat IgG2b, clone 7E.17G9, BioXCell) or rat IgG2b isotype control 1 day before and 2 days after cell transfer (0.5 mg per mouse per injection). To block IL-2, two doses of recombinant CD25 protein (25 μg per mouse per dose, Sino Biological) were injected into mice at the same time with immunization or 1 day after immunization. Flow cytometry and cell sorting. All antibody conjugates were from Biolegend or BD Biosciences. EBI2 surface staining, T-cell staining, germinal centre B cell staining and intracellular Ig staining for plasma cells were performed as described 17, 31 . EBI2 surface staining was performed with a goat polyclonal antibody against the amino (N) terminus (clone A20, Santa Cruz Biotechnology) as described 17 . Tfh cell staining was performed with antibodies including biotin-conjugated anti-CXCR5 (BD Biosciences), PE-Cy7-conjugated anti-PD-1 (clone RMP1-30, Biolegend) and Alexa 647-conjugated anti-Bcl6 (clone k112-91, BD Biosciences) as described 36 . Staining of CD25 on splenic or lymph node DC was performed using Alexa 647-conjugated anti-CD25 (clone PC61, Biolegend), PE-Cy7-conjugated anti-CD11c (clone N418, Tonbo Biosciences), FITC-conjugated anti-I-A b (clone AF6-120.1, BD Biosciences), PE-conjugated anti-DCIR2 (clone 33D1, eBioscience) or PE-conjugated anti-CD11b (clone M1/70, Biolegend), Pacific Blue-conjugated anti-CD8a (clone 53-6.7, Biolegend) and biotin-conjugated anti-CD103 (clone 2E7, Biolegend). To assess pSTAT5 levels directly ex vivo, spleens were immediately mashed using cell strainers into Cytofix/Cytoperm buffer (BD Biosciences). For peripheral lymph node analyses, the brachial, axillary and inguinal lymph node were pooled. After fixation for 30 min at 37 °C, the cells were washed, resuspended in Perm Buffer III (BD Biosciences) and incubated on ice for 30 min. After an additional wash, cells were stained for surface and intracellular antigens, including pSTAT5 (pY694, BD Biosciences), for 45 min at room temperature. Where indicated, 4 μg of human IL-2 was injected intravenously into mice 2 h before analysis as a positive control for pSTAT5. Data were collected on an LSRII and a FACSVerse (BD Biosciences) and were analysed with FlowJo software (TreeStar). DCs, OTII CD4 + T cells or Tfh cells were sorted using a FACSAria III (BD) as described 31 . Transwell migration assay. Splenocytes were allowed to transmigrate for 4 h across 5 μm transwell filters (Corning Costar) towards medium or 7α,25-OHC (Avanti Polar Lipids) and enumerated by flow cytometry as described 17 . Immunohistochemistry and immunofluorescence microscopy. Cryosections of 7 μm were fixed and stained immunohistochemically as described 17, 31 with: FITC-conjugated anti-IgD (clone 11-26c.2a, BD Biosciences), biotin-conjugated anti-CD45.1 (clone A20, Biolegend), biotin-conjugated anti-DCIR2 (clone 33D1, Biolegend) or biotin-conjugated anti-CD25 (clone PC61.5, BD Biosciences) followed by HRP-conjugated anti-FITC, AP-conjugated anti-FITC, and/or AP-conjugated SA (Jackson Immunoresearch). For staining of DCIR2 and CD25, a tyramide amplification kit was used (TSA Biotin System; Perkin Elmer). For immunofluorescence, staining was performed with biotin conjugated anti-CD45.1, rabbit anti-GFP (Molecular Probes), and goat anti-mouse IgD (GAM/IGD(FC)/7S, Cedarlane Laboratories), followed by AMCA-conjugated donkey anti-goat IgG (Jackson Immunoresearch), Alexa 488-conjugated donkey anti-rabbit IgG and Alexa 647-conjugated streptavidin (Invitrogen). Images were captured with a Zeiss AxioOberver Z1 inverted microscope. Image quantification. Immunofluorescence images were analysed using IMARIS (version 7.3.0). White-pulp cords containing circular T zones were used to quantify outer T-zone positioning of co-transferred WT (red) and EBI2 HET or KO cells (green). OTII cells were defined using the Spots function in IMARIS and coordinates for each OTII cell were exported into R. The centre and average radius of the T zone was measured using the Measurement Points function in IMARIS. The 'outer T zone' was defined as the area further than three-quarters of the average radius from the centre of the T zone. The distance of each OTII cell from the centre of the T zone and the proportion of cells in the outer T zone was calculated using R. An average of 70 cells were present for each co-transferred group per T zone (average of 140 total). IHC images were analysed manually using the Cell Counter Plugin in ImageJ (version 1.49). OTII cells that were in contact with DCIR2 + DC were distinguished from lone OTII cells using separate counters. Soluble CD25 ELISA and bioassay. To test the production of sCD25 by DCs in vitro, mice were first intraperitoneally immunized with SRBCs. At the time of analysis, spleen CD4 + DCs were enriched by depletion of T, B and natural killer (NK) cells with a cocktail of biotin-conjugated antibodies and isolated by positive selection using biotin-conjugated anti-DCIR2 to purities of over 90% (Miltenyi Biotec). The purified DCs were cultured in vitro for 8 h and the presence of soluble CD25 in culture supernatants was detected using a CD25 ELISA kit (R&D Systems). To detect sCD25 in spleen tissue, each spleen was mashed into 1 ml of medium through a 70 μm cell strainer and centrifuged at 300g for 10 min and 3,000g for 15 min at 4 °C. The cell-free supernatant was subjected to the ELISA assay. To test for antagonism of IL-2 mediated signalling, DC culture supernatants were mixed with different dosages of recombinant mouse IL-2 (Biolegend) for 2 h and added to splenocytes at 37 °C for 30 min. pSTAT5 levels in CD25 + CD4 + T cells were analysed as described above. Detection of SRBC-or HEL-specific antibody responses. To assay for anti-SRBC or anti-HEL IgM and IgG from mouse serum, 50 μl of SRBCs or HEL-conjugated mouse RBCs (5 × 10 7 cells per millilitre in PBS) were incubated with 2 μl of serum for 1 h at room temperature. After washing, the RBCs were incubated with fluorescent antibodies against mouse IgM, IgG1 and IgG2b for flow cytometric analysis. Quantitative RT-PCR. Total RNA from sorted cells was isolated and reversetranscribed, and quantitative PCR was performed as described 31 . Data were analysed using the comparative C T (2 −ΔΔCt ) method using Hprt as the reference. RNA-seq analysis. Spleens were taken 1 h after saline or SRBC immunization. CD4 + DCs were pre-enriched using MACS manual cell separation columns with anti-CD11c microbeads (Miltenyi Biotec) and further sorted on the basis of surface markers of CD11c + I-Ab + CD4 + CD8 − . Cells were sorted twice on a FACSAira III to purities of over 99%. Sorted DCs (10 6 ) were snap frozen and then RNA was extracted with the QIAGEN RNeasy Kit. RNA quality was checked with an Agilent 2100 Bioanalyzer (RNA integrity number >9 for all samples). Barcoded sequencing libraries were generated with 100 ng of RNA with an Ovation RNA-Seq System V2 and Encore Rapid Library System. Sequencing was performed on an Illumina HiSeq 2500 (UCSF Human Genetics Core) with 100-base-pair paired-end reads. Sequences were reported as FASTQ files, which were aligned to the mm9 mouse genome with STAR (Spliced Transcript Alignment to a Reference). Generation of log 2 FC values and further analyses were performed with a Bioconductor package on RStudio. The RNA-seq data have been deposited in the Gene Expression Omnibus (NCBI) data repository under accession code GEO: GSE71165. 
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Extended Data Figure 4 | T-cell EBI2 is required for CD4 + DCmediated augmentation of Tfh cell induction. a, Frequency and number of CXCR5 + PD-1 hi OTII T cells in μMT recipients determined by flow cytometric analysis. b, Flow cytometric analysis for CD11c and MHC class II on splenocytes from Zbtb46-DTR mice treated with saline or DT for 1 day. Graph shows summary data for DC number in four mice of each type. c, Frequency and number CXCR5 + PD-1 hi WT and EBI2 KO OTII T cells in spleens from Zbtb46-DTR BM chimaeras treated with saline or diphtheria toxin (DT), at day 3 after immunization with SRBC-OVA. d, Immunohistochemical analysis of spleen sections from WT mice without immunization (saline) or SRBC immunized for the indicated times, stained to detect IgD + B cells (blue) and DCIR2 + DCs (brown). e, Immunohistochemical analysis of spleen sections from recipients of WT or EBI2 KO OTII T cells at 12 h and 1 day after immunization SRBC-OVA immunization, stained for OTII CD45.1 + T cells (blue) and DCIR2 + DCs (brown). f, Immunohistochemical analysis of spleen sections from WT:Zbtb46-DTR or CCR7 KO:Zbtb46-DTR mixed BM chimaeras treated with DT, at day 2 after immunization. g, Frequency and number of CXCR5 + PD-1 hi WT and EBI2 KO OTII T cells in spleens from WT:Zbtb46-DTR (control) or CCR7 KO:Zbtb46-DTR mixed BM chimaeras treated with DT, at day 3 after immunization. h, Frequency and number of CXCR5 + PD-1 hi control (het) and EBI2 KO co-transferred OTII T cells in spleens of CD47 KO recipients at day 3 after SRBC-OVA immunization. i, Number of total and CD4 + DC in spleens from Irf4 f/f CD11c-Creor + mice. j, As for g but in Irf4 f/f CD11c-Creor + recipient mice. k, As for g but in Batf3 KO recipient mice. l, ICOSL surface levels for DCs from mice immunized 12 h earlier with saline or SRBCs and treated with control or ICOS blocking antibody. m, ICOSL surface levels for CD4 + or CD8 + DCs from CD28 KO mice immunized 12 h earlier with saline or SRBCs. n, Il6 and Tgfβ mRNA abundance in sorted CD4 + and CD8 + splenic DCs from mice treated with saline or SRBC 6 h earlier, determined by RT-qPCR, shown relative to the control CD8 + DC. **P < 0.01 by ANOVA (g, k) or Student's t-test (a-c, i, j, m) . Data are representative of three (a-e) or two (f-n) independent experiments with at least three (a-c, g-n) or two (d-f) mice per group (error bars (n), s.e.m.).
